Suppr超能文献

对丙酸交沙霉素(一种动力学高度可变的药物)在健康志愿者中进行的多剂量生物等效性研究。

Multiple dose bioequivalence study with josamycin propionate, a drug with highly variable kinetics, in healthy volunteers.

作者信息

Van Hoogdalem E J, Terpstra I J, Krauwinkel W J, Volkers-Kamermans N J, Baven A L, Verschoor J S

机构信息

Yamanouchi Europe B.V., Research Labs Leiderdorp, The Netherlands.

出版信息

Int J Clin Pharmacol Ther. 1996 May;34(5):202-7.

PMID:8738856
Abstract

Josamycin is a macrolide antibiotic with considerable intra- and interindividual variability in kinetics. In the present study bioequivalence of an intact and dispersed josamycin Solutab tablet, containing 1,000 mg of josamycin in the form of josamycin propionate ester, was tested versus a Josacine 1,000 mg reference sachet. The design of this bioequivalence study was adapted to the drug's pharmacokinetic variability, comprising testing in steady-state, testing the reference in replicate, and maintaining a widened bioequivalence margin. The study was performed in a group of 24 male and 12 female healthy subjects, according to a 3-treatment 4-period crossover design. Blood sampling for establishing josamycin propionate and josamycin base serum level profiles were collected during the 12 h dosing interval on day 4. Steady-state serum levels were reached on day 4. With the reference sachet mean peak levels of 1.02 micrograms/ml and 0.36 microgram/ml were observed for parent drug and metabolite, respectively, reached at peak times of 1.5 h and 1.8 h. Comparable profiles were observed with the intact and dispersed Solutab tablets, both tending towards higher serum levels than the sachet. In terms of josamycin propionate levels as well as josamycin base levels, the intact and dispersed Solutab tablet was bioequivalent with the referent sachet within the preset 0.70-1.43 margins. Variability in josamycin kinetics proved to be substantial, maximum differences in peak levels and AUC values being about 10-fold between individuals, and 3-fold within individuals. Retrospectively, the multiple dosing regimen appeared not to result in a clear reduction of intrasubject variability.

摘要

交沙霉素是一种大环内酯类抗生素,其动力学存在显著的个体内和个体间差异。在本研究中,对含1000mg丙酸交沙霉素酯形式的交沙霉素的完整和分散型Solutab片剂与1000mg交沙霉素参考药袋进行了生物等效性测试。本生物等效性研究的设计适应了该药物的药代动力学变异性,包括稳态测试、参考药重复测试以及维持较宽的生物等效性界限。该研究按照3治疗组4周期交叉设计,在24名男性和12名女性健康受试者中进行。在第4天的12小时给药间隔内采集血样以建立丙酸交沙霉素和交沙霉素碱的血清水平曲线。第4天达到稳态血清水平。使用参考药袋时,母体药物和代谢物的平均峰值水平分别为1.02μg/ml和0.36μg/ml,在1.5小时和1.8小时达到峰值时间。完整和分散型Solutab片剂观察到类似的曲线,两者的血清水平均倾向于高于药袋。就丙酸交沙霉素水平以及交沙霉素碱水平而言,完整和分散型Solutab片剂在预设的0.70 - 1.43界限内与参考药袋生物等效。交沙霉素动力学的变异性被证明很大,个体间峰值水平和AUC值的最大差异约为10倍,个体内为3倍。回顾性分析,多次给药方案似乎并未导致受试者内变异性明显降低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验